Ann Oncol. 2024 Dec 18. IF: 56.7Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2+ early breast cancer (EBC).www.annalsofoncology.org/article/S0923-7534(24)04989-5/fulltext Nat Cancer. 2024 Dec 20;5:1940-1961. IF: 23.5Dura immunity configures leptomeningeal metastasis immunosuppression for cerebrospinal fluid barrier invasion.www.nature.com/articles/s43018-024-00858-2 JAMA Netw Open. 2024 Dec 20;7(12):e2451827. IF: 10.5Disparities and Gaps in Breast Cancer Screening for Women Aged 40 to 49 Years.www.jamanetwork.com/journals/jamanetworkopen/fullarticle/2828312 Acta Biomater. 2024 Dec 19. IF: 9.4Engineered Microalgae for Photo-Sonodynamic Synergistic Therapy in Breast Cancer Treatment.www.sciencedirect.com/science/article/pii/S1742706124007669 Nat Biomed Eng. 2024 Dec 20. IF: 26.8Advancing breast cancer risk stratification using multimodal AI.www.nature.com/articles/s41551-024-01304-5 Cancer Treat Rev. 2024 Dec 19;132:102865. IF: 9.6Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis.www.cancertreatmentreviews.com/article/S0305-7372(24)00194-4/fulltext Proc Natl Acad Sci U S A. 2024 Dec 20;121(52):e2402849121. IF: 9.4Docetaxel response in BRCA1,p53-deficient mammary tumor cells is affected by Huntingtin and BAP1.www.pnas.org/doi/10.1073/pnas.2402849121
